May 27 2022




Recommendations

No information is available about the adverse effects of this substance on breastfed infants or the possible alteration of breastfeeding. As in the case of other anticonvulsants, the influence of other drugs taken together greatly influences the concentration of zonisamide, so that this varies depending on the composition of the drugs taken together .

The small number of publications available seems to suggest that, at usual doses, this drug accumulates in milk at concentrations higher than other anticonvulsants, although gradually decreases over time. Judging from the known data, the cumulative amount of zonisamide in milk is a percentage of 28-30% of the weight-adjusted maternal dose.

If deemed necessary to administer this substance, the baby should be closely monitored, especially somnolence and weight developmental abnormality or neuromotor maturation.

Warning of the manufacturer:

Zonisamide is excreted in breast milk; the concentration in breast milk is similar to that of maternal plasma. It is deemed necessary to choice between to stop breastfeeding or stop therapy with zonisamide. Since the retention time of this drug in the body is long, do not resume breastfeeding until one month after completion of therapy with this drug.

Updated:26.03.08